pipette
ENEnglish

Domain-alteration chimeras rewire oncogenic complexes in prostate cancer

Jie Luo, Jianzhang Yang, Jean Ching-Yi Tien, Mi Wang, Sumit Das, Xiaoju Wang, Eleanor Young, Jelena Tošović, Rahul Mannan, Weiguo Xiang, Xia Jiang, Jocelyn Cai, Yihan Liu, Kenneth Gu, Somnath Mahapatra, Shiting Li, Yitong Yin, Sanjana Eyunni, Abigail J. Todd, Shicheng Jin, Xuhong Cao, Fengyun Su, Stephanie J. Miner, Ranga Sudharshan, Arvind Rao, Abhijit Parolia, Yuanyuan Qiao, Shaomeng Wang, Arul M. Chinnaiyan

Revista con revisión por paresAfirmaciones fuertes, leer con cuidadoDice ser un gran avanceUso en el mundo real

En palabras de los autores

Abstract Transcriptional addiction to the androgen receptor (AR) underlies metastatic castration-resistant prostate cancer 1 , in which AR maintains oncogenic programs through domain-specific interactions with the acetyltransferases p300 and CBP (collectively p300/CBP) 2 . Here we describe a novel therapeutic modality, domain-alteration chimeras (DALTACs), that rewire endogenous protein complexes by enforcing non-native domain–domain interactions. Our first-in-class AR–p300/CBP DALTAC-1 induces synthetic proximity between the ligand-binding domain of AR and the bromodomain of p300/CBP, misconfiguring their native interface and locking the complex in a non-productive state. DALTAC-1 triggers a ‘super-inhibitory’ effect, suppressing AR-driven transcription and proliferation more potently than combined AR and p300/CBP inhibition. Mechanistically, DALTAC-1 reprograms p300/CBP substrate engagement, abolishing the histone mark H2B N-terminal acetylation and inducing neomorphic acetylation of AR and coactivators, ultimately collapsing the AR neo-enhanceosome. Chromatin profiling revealed redistribution of AR and p300/CBP towards palindromic androgen response elements, accompanied by disruption of cofactor and transcriptional machinery recruitment at oncogenic AR and ERG neo-enhancers. DALTAC-1 exhibits exquisite lineage selectivity, displaying potent activity in AR–p300/CBP dual-dependent cells and sparing AR-negative cells. In multiple in vivo models, DALTAC-1 induces deep and durable tumour regressions. Together, these findings establish DALTACs as a broadly applicable strategy to rewire disease-defining complexes through domain-topology alteration, expanding induced-proximity therapies, and the precise lineage selectivity of DALTAC-1 supports its translational potential in AR-driven prostate cancer.

Resultado principalEl resumen no menciona limitaciones.

Apareció: viernes, 13 de noviembre. Nature. Revista con revisión por pares.

DOI: 10.1038/s41586-026-11262-4